GlassScriptPhysician profile
Amber Besselman
NPI 1063268852
$6,718.47
in general payments reported to CMS, 2019-2025
39 companies · $4,149 in 2025
The $4,149 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,569 · 2025: $4,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,702 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,701.75 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $823.95 | 2024-2025 | |
| Ucb, INC. | $531.59 | 2024-2025 | Nayzilam, Zilbrysq, Briviact |
| Lilly USA, LLC | $530.98 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $522.90 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $437.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $401.18 | 2024-2025 | |
| Axsome Therapeutics, INC. | $275.69 | 2025 | Symbravo, Sunosi |
| Otsuka America Pharmaceutical, INC. | $266.06 | 2024-2025 | Rexulti |
| Lundbeck LLC | $250.96 | 2024-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $236.58 | 2024-2025 | Xcopri |
| Argenx US, INC. | $219.06 | 2024-2025 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $203.51 | 2024-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $183.74 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $167.36 | 2024-2025 | Hyqvia, Trintellix |
| Genentech USA, INC. | $146.39 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $133.70 | 2024-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $132.74 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Merz Pharmaceuticals, LLC | $128.49 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Eisai INC. | $116.46 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $94.51 | 2024-2025 | Nuplazid |
| Mallinckrodt Hospital Products INC. | $89.43 | 2024-2025 | Acthar |
| Averitas Pharma INC. | $85.98 | 2025 | Qutenza |
| Grifols USA, LLC | $81.37 | 2024-2025 | Gamunex-C |
| Vanda Pharmaceuticals INC. | $74.61 | 2025 | Ponvory |
| Amgen INC. | $66.80 | 2025 | Uplizna |
| Emd Serono, INC. | $60.59 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $57.43 | 2025 | Lumryz |
| Amneal Pharmaceuticals LLC | $51.27 | 2025 | Crexont |
| Mdd US Operations, LLC | $47.70 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $43.42 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $38.31 | 2024-2025 | Amvuttra, Givlaari |
| Tanabe Pharma America, INC. | $37.98 | 2025 | Radicava |
| Astrazeneca Pharmaceuticals LP | $36.79 | 2025 | Wainua |
| Biogen, INC. | $33.88 | 2025 | Leqembi, Vumerity |
| Ge Healthcare | $26.61 | 2024 | |
| Inspire Medical Systems, INC. | $25.54 | 2025 | Inspire |
| Boston Scientific Corporation | $23.01 | 2024 | |
| Cala Health, INC. | $19.75 | 2025 | Cala Kiq |
| Xeris Pharmaceuticals, INC. | $14.70 | 2024 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Besselman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.